EyePoint reported unfavorable pivotal Phase 3 results for its experimental therapy in wet age-related macular degeneration (wet AMD), undermining the case for approval against the current standard of care. The report indicates the program missed the main goal of the study, triggering a steep market reaction. EyePoint’s shares dropped sharply at the open following the company’s disclosure that its drug did not meet the primary objective in the wet AMD trial. Despite the setback, the company and analysts reportedly still see potential for a path forward, but the immediate impact is increased investor uncertainty. For developers in ophthalmology, the episode highlights how quickly late-stage efficacy signals can change approval prospects and capital allocation, especially in highly competitive retina markets dominated by established agents.